Getinge AB (publ) (BIT:1GETI)

Italy flag Italy · Delayed Price · Currency is EUR
17.45
-0.48 (-2.70%)
At close: Jun 2, 2026
Market Cap4.67B -2.8%
Revenue (ttm)3.11B -4.1%
Net Income214.99M +59.5%
EPS0.79 +59.5%
Shares Out n/a
PE Ratio21.70
Forward PE15.30
Dividend0.44 (2.46%)
Ex-Dividend DateApr 22, 2026
Volumen/a
Openn/a
Previous Close17.93
Day's Rangen/a
52-Week Range16.09 - 22.59
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateJul 17, 2026

About Getinge AB

Getinge AB (publ) provides products and solutions for operating rooms, intensive-care units, and sterilization departments in Sweden and internationally. The company operates through Acute Care Therapies, Life Science, and Surgical Workflows segments. It offers extracorporeal membrane oxygenation, mechanical ventilation, advanced patient monitoring, ICU infrastructure equipment, and drainage solutions. In addition, the company provides surgical perfusion, endoscopic vessel harvesting, intra-aortic balloon counterpulsation, vascular and cardioth... [Read more]

Industry Electromedical and Electrotherapeutic Apparatus
Founded 1904
Employees 11,754
Stock Exchange Borsa Italiana
Ticker Symbol 1GETI

Financial Performance

In 2025, Getinge AB's revenue was 34.97 billion, an increase of 0.60% compared to the previous year's 34.76 billion. Earnings were 2.26 billion, an increase of 37.85%.

Financial numbers in SEK Financial Statements

News

Getinge maintains FY26 organic sales growth view of 3%-5%

There is currently high geopolitical uncertainty, however, based on dialogue with its customers Getinge (GNGBY) is maintaining the forecast of organic sales growth of 3-5% in 2026. Published first on…

6 weeks ago - TheFly

Getinge AB Earnings Call Transcript: Q1 2026

Organic net sales grew 0.8% year-over-year, with strong order intake and solid cash flow despite SEK 226 million in tariff and currency headwinds. Life Science and Surgical Workflows led growth, while guidance for 2026 organic net sales growth of 3%-5% was reiterated.

6 weeks ago - Transcripts

Getinge AB Quarterly report: Q1 2026

Getinge AB has published its Q1 2026 quarterly earnings report on April 21, 2026.

6 weeks ago - Filings

Getinge AB Slides: Q1 2026

Getinge AB has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 21, 2026.

6 weeks ago - Filings

Getinge AB Earnings Call Transcript: Q4 2025

Record organic sales growth in Q4 2025 was driven by strong performance in Acute Care Therapies and Surgical Workflows, while Life Science lagged. Margin expansion remains a focus for 2026 despite ongoing tariff and FX headwinds, with 3%-5% organic net sales growth guided.

4 months ago - Transcripts

Getinge AB Annual report: Q4 2025

Getinge AB has published its Q4 2025 annual report on January 27, 2026.

4 months ago - Filings

Getinge AB Quarterly report: Q4 2025

Getinge AB has published its Q4 2025 quarterly earnings report on January 27, 2026.

4 months ago - Filings

Getinge AB Slides: Q4 2025

Getinge AB has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on January 27, 2026.

4 months ago - Filings

Getinge upgraded to Buy from Hold at Nordea

Nordea analyst Ludvig Lundgren upgraded Getinge (GNGBY) to Buy from Hold with a SEK 245 price target

8 months ago - TheFly

Getinge downgraded to Hold from Buy at Pareto

Pareto downgraded Getinge (GNGBY) to Hold from Buy with a SEK 245 price target

8 months ago - TheFly

Getinge AB Earnings Call Transcript: Q3 2025

Strong organic growth and margin improvement in Q3, led by ACT and Life Science, offset tariff and FX headwinds. Solid financial position and guidance for 2%-5% organic net sales growth in 2025 are maintained, with ongoing focus on quality, productivity, and cost control.

8 months ago - Transcripts

Getinge AB Quarterly report: Q3 2025

Getinge AB has published its Q3 2025 quarterly earnings report on October 21, 2025.

8 months ago - Filings

Getinge AB Slides: Q3 2025

Getinge AB has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on October 21, 2025.

8 months ago - Filings

Medical gear maker Getinge tops core profit estimates in third quarter

Swedish medical equipment maker Getinge reported third-quarter core earnings above market expectations on Tuesday, supported by price adjustments to combat a hit from U.S. tariffs and negative currenc...

8 months ago - Reuters

Getinge price target lowered to SEK 175 from SEK 182 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 175 from SEK 182 and keeps an Equal Weight rating on the shares.

11 months ago - TheFly

Getinge price target lowered to SEK 165 from SEK 191 at JPMorgan

JPMorgan lowered the firm’s price target on Getinge (GNGBY) to SEK 165 from SEK 191 and keeps an Underweight rating on the shares.

11 months ago - TheFly

Getinge AB Earnings Call Transcript: Q2 2025

Solid organic growth and margin improvement achieved despite significant tariff and FX headwinds, with strong performance in Acute Care Therapies and Surgical Workflows. Financial position remains robust, and 2025 guidance for 2–5% organic net sales growth is reaffirmed.

11 months ago - Transcripts

Getinge AB Quarterly report: Q2 2025

Getinge AB has published its Q2 2025 quarterly earnings report on July 18, 2025.

11 months ago - Filings

Getinge AB Slides: Q2 2025

Getinge AB has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on July 18, 2025.

11 months ago - Filings

Getinge price target lowered to SEK 182 from SEK 191 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 182 from SEK 191 and keeps an Equal Weight rating on the shares.

1 year ago - TheFly

Getinge initiated with a Market Perform at Bernstein

Bernstein analyst Delphine Le Louet initiated coverage of Getinge (GNGBY) with a Market Perform rating and SEK 228 price target The firm notes Getinge is a global leader in hospital…

1 year ago - TheFly

Getinge price target lowered to SEK 191 from SEK 197 at Morgan Stanley

Morgan Stanley lowered the firm’s price target on Getinge (GNGBY) to SEK 191 from SEK 197 and keeps an Equal Weight rating on the shares.

1 year ago - TheFly

Getinge AB Earnings Call Transcript: Q1 2025

Order intake rose 7.1% and net sales grew 10.7% year-over-year, led by acute care therapies and Americas. Margins improved despite FX headwinds, and leverage remains stable post-acquisition. 2025 outlook is for 2–5% organic sales growth, with ongoing market and tariff uncertainties.

1 year ago - Transcripts

Getinge AB Quarterly report: Q1 2025

Getinge AB has published its Q1 2025 quarterly earnings report on April 22, 2025.

1 year ago - Filings

Getinge AB Slides: Q1 2025

Getinge AB has posted slides in relation to its Q1 2025 quarterly earnings report, which was published on April 22, 2025.

1 year ago - Filings